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1 Introduction
Completion of the Human Genome Project 
was announced on April 14, 2003, as the whole 
human genome was sequenced.  The Human 
Genome Project was proposed in the mid-1980s 
aiming to sequence the whole human genome. 
Yet, its realization was thought to be almost 
impossible since a considerable amount of time 
was required to complete the whole genome 
sequencing with the analysis technology at that 
time.  Later on, however, the human genome 
research advanced rapidly and the international 
Human Genome Project started in 1990 with 
the U.S. playing the leading role.  When the 
project was launched, it was planned to sequence 
the whole human genome of about 3 Gbp 
and identify all of the 30,000 genes by 2005. 
However, early completion of the whole genome 
sequencing was proclaimed in April 2003, mainly 
because of the great improvements in analyzers[1].
Some people regard the structural genome 
analysis technology as fully matured because it 
has developed dramatically through the Human 
Genome Project in recent years and sequencers 
have become widely used.  Yet, in this era of 
post genome research, “high-speed and low-cost 
analysis” is further required.  It is thought that 
the application of conventional technology is 
insufficient to meet such requirements and the 
invention of new technology is necessary.
In this report, we will discuss the current 
status of research and development of structural 
genome analysis technology and the necessity for 
their promotion.
2 Structural and 
 functional genome analyses
Genome analysis comprises of structural and 
functional studies.
In structural genome analysis, the sequence 
of DNA’s four bases is clarified.  The genome is 
the total of the genetic information.  The human 
genome, for example, is contained in the 24 
chromosomes consisting of 22 autosomes and 
two sex chromosomes.  DNA carries the genetic 
information and has four bases of adenine (A), 
guanine (G), cytosine (C) and thymine (T).  The 
total size of the human genome is about 3 Gbp. 
DNA sequences vary among individuals and this 
Figure 1:Structural and functional genome analysis
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phenomenon is called genetic polymorphism. 
Structural genome analysis has been carried 
out by sequencing the DNA from an end and 
comparing the unknown sequence with already 
known sequences.
In contrast, in functional genome analysis, 
ge nome  s e que nce s  a r e  cor r e l a t e d  w i t h  
phenotypes.  In other words, the gene that has 
the information for producing a protein and 
the domains that control the production of the 
protein are identified and the function of the 
protein is characterized.
3  Development of the
 structural genome analysis
 technology
Structural genome analysis has been carried 
out by sequencing the DNA from an end (DNA 
sequencing technology) and comparing the 
sequence of a DNA sample with already known 
sequences fixed on a substrate based on the 
binding activity of the hybridized DNAs.
Frederick Sanger disclosed the Sanger method*1 
and Allan Maxam and Walter Gilbert disclosed 
the Maxam-Gilbert method almost at the same 
time in 1977, as the principles for sequencing the 
single-strand DNA.  At that time, DNA sequencing 
had been carried out manually using radiation 
detection, so a researcher could sequence 1,000 
bp at most in a year[2].  Since the Sanger method 
was more suitable for automation than the 
Maxam-Gilbert method, the Sanger method came 
to be used widely.
In 1982, Akiyoshi Wada of the University 
of Tokyo proposed the development of the 
automated sequencer and invention of element 
technologies for its real ization started.  In 
1986, Leroy Hood, Lloyd Smith and colleagues 
disclosed the first automated sequencer.  Then, 
in 1987, Applied Biosystems Inc. marketed the 
first automated sequencer with Hood’s principle 
applied.  Furthermore, in 1990, sequencers based 
on capillary electrophoresis were developed by 
three groups led by Lloyd Smith, Barry Karger 
and Norman Dovichi, respectively.  Meanwhile, 
from 1992 to 1993, R ichard Mathies and a 
group led by Hideki Kambara of Hitachi Ltd. 
unveiled sequencers based on the capillary-array 
electrophoresis.  Molecular Dynamics and PE 
Table 1: Chronology of genome-related technology
1953 Discovery of the double helical structure J. Watson and F. Crick
1972 Invention of the DNA recombination technology P. Berg and S. Cohen
1977
Invention of the DNA sequencing method 
(Sanger method, Maxam-Gilbert method)
F. Sanger, A. Maxam, and W. 
Gilbert
1980 Proposal of genome mapping by restriction fragment length polymorphism (RFLP)
D. Botstein, R. Davis,
 M. Skolnick, R. White
1982 Proposal of the automated sequencing system A. Wada
1984 Development of the pulsed field gel electrophoresis C. Cantor, D. Schvartz
1985 Invention of the polymerase chain reaction (PCR) K. Mullis
1986 Development of the autosequencer Invention of a heat-resistant enzyme for PCR L. Hood, L. Smith, Mullis, K. Saiki
1987
Development of the yeast artificial chromosome (YAC)
Autosequencers marketed
D. Burke, M. Olson, G. Carle
Applied Biosystems inc.
1989 Development of mapping with the sequence tagged site (STS) Olson, Hood, Botstein, Cantor
1990 Invention of the capillary electrophoresis Karger, Smith, N. Dovichi
1992 Development of the bacterial artificial chromosome (BAC) M. Simon
1993 Development of the capillary array electrophoresis H. Kambara
1995 Invention of the DNA microarray P. Brown
1996 DNA chips marketed Affymetrix
1997 Capillary DNA sequencers marketed Molecular Dynamics
1998 Capillary DNA sequencers marketed PE Biosystems Inc.
Source:  Authors’ compilation on the basis of information provided by Prof. Yoshinobu Baba of the Faculty of Pharmaceutical Sciences at 
the University of Tokushima and the reference[3].
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Biosystems Inc. brought capillary sequencing 
m ach i ne s  to  m a rke t  i n  19 97  a nd  19 9 8 ,  
respectively[3].  Capillary sequencing machines 
are the most widely used among sequencers 
today.
Assay, detection and analysis of a sample are 
automated in the capillary sequencing machine. 
Since electrophoresis, which is the sample 
assaying process, is conducted in capillaries, high 
speed and an advanced separation property are 
obtained.  We can sequence as much as 748,800 
bp a day with today’s capil lary sequencing 
machine (The Applied Biosystems 3730 DNA 
Analyzer is equipped with 48 capi l lar ies. 
According to its standard protocol, about 650 
bp can be sequenced with a capillary at a time 
and an hour is required for this process)[4].  In 
this way, the sequencing technology has been 
innovated based on the Sanger method and 
analysis capacity has been boosted.
In the meantime, in order to detect single 
nucleotide polymorphism (SNP) and screen gene 
expression, we use the microarray and the DNA 
chip*2, in which the sample is hybridized with 
the DNA fixed on the substrate, the difference 
in sequence between the sample and the fixed 
DNA is detected, and the sequence of the 
sample is analyzed.  We can also directly analyze 
the sequences that genetically vary between 
individuals such as SNP by decoding the sequence 
one by one from an end and comparing the 
sequence with a known sequence.  Yet, such 
analysis can be done much easier with the 
microarray or the DNA chip: We can analyze 
a number of SNPs at the same time with these 
methods.  However, they are stil l imperfect 
technolog ies and there are hurdles to be 
overcome such as the noise caused by unspecific 
adsorption to the substrate.
In connection with this, Patrick Brown and 
colleagues published in 1995 the first paper on a 
microarray in which cDNA probes are applied to 
a glass plate, and Affymetrix produced DNA chips 
for commercial use in 1996[3].
4 Structural genome analysis
 technology in
 post genome research
As the Human Genome Project was completed 
and post genome researches have been launched, 
the object of study has developed from structural 
genome analysis to clarification of the entire 
biological phenomena and applications of genome 
studies in medicine and pharmacy.
As the next step to structural genome analysis, 
researchers are pushing forward functional 
genome analysis, in which the position and 
function of genes are character ized based 
on the DNA sequence, biomolecular studies, 
such as characterization of protein structures 
and functions and research on sugar chains, 
and studies at the cell, tissue and individual 
levels.  We still need to analyze the structure 
of related genes in such studies.  Moreover, 
besides researches on individual molecules, we 
need to pursue comprehensive studies such 
as transcriptome analysis, in which the whole 
mRNAs existing in a cell at a certain stage are 
analyzed, and proteome analysis, in which 
production of all proteins in a cell is studied. 
Technology for realizing highly efficient analysis 
is essential in these studies.
Also, researchers are promoting research and 
development for boosting functional analysis 
based on decoded genome sequences and for 
exploiting its fruits.  For instance, the difference 
in genome sequences between individuals is said 
to be a genetic factor related to the incidence 
of diseases and drug sensitivity.  Researchers 
are pursuing the development of new ways 
of diagnosis, treatment and prevention of 
diseases by accumulating information on genes 
involved in complex diseases such as cancers 
and lifestyle -related diseases and by clarifying 
the mechanism causing their development. 
Fur thermore,  researchers a re s t r iv ing to 
invent new pharmaceuticals by unveiling the 
characteristics of genes related to drug sensitivity.
In order to achieve such objects, it is necessary 
to statistical ly compare genome sequences 
of individuals and search for genes related to 
diseases and drug sensitivity.  Therefore, we 
14
S C I E N C E  &  T E C H N O L O G Y  T R E N D S
need to analyze statistically a number of human 
genome sequences.  We have only clarified a 
single set of the human genome in the Human 
Genome Project.  As shown in Figure 2, although 
the number of sequences registered in the DNA 
Data Bank of Japan (DDBJ), which is a major 
international DNA database, has increased 
exponentially from the 1970s up to now, it has 
only reached 30 Gbp as of March 2003, including 
not only human genomes but also genomes of 
all other organisms like Escherichia coli and 
nematodes[5].  Since a set of human genome is 3 
Gbp, we understand well that we need massive 
analysis for statistical use, and it is crucial to 
invent technology for analyzing structures of 
huge amounts of genomes more efficiently than in 
conventional methods.
Furthermore, lowering the analysis cost is 
essential in order to realize medical treatment 
using genomic information and to employ it 
in clinical use and for individual treatments as 
genomic-based testing tools, for example.
In the meantime, there are various fields other 
than medicine and pharmacy that may benefit 
from the development of structural genome 
analysis technology.
Breed i ng  of  p l a nt s  a nd  a n i ma l s  ba sed  
on genomic in formation and invention of 
health - promoting foods are being pursued 
in the agr iculture and food industry.  The 
Figure 2:Roadmap of DNA sequencing
Source:  Provided by Prof. Yoshinobu Baba of the Faculty of Pharmaceutical Sciences at 
the University of Tokushima.
Figure 3: Applications of genome analysis technology
Source:  Partly Compiled by the authors on the basis of information provided by Prof. 
 Yoshinobu Baba of the Faculty of Pharmaceutical Sciences at the University
 of Tokushima.
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genetically modified crops popularized so far 
bring such advantages as decreasing the amount 
of agrichemicals, al leviating farm work and 
increasing harvest with herbicide and vermin 
resistance added.  Today, researchers are 
accelerating research and development of crops 
with high productivity, resistance to soil stresses 
and nutritional value.  Meanwhile, it is hoped 
that microbe genomes will be used in medicine, 
pharmacy, chemical production and processing, 
and environmental conservation.  Functional 
ana lysis of microbes using thei r genomic 
information is promoted to exploit microbe 
genomes in chemical production and processing 
and bioremediation, i.e., removing pollutants and 
restoring the environment using microbes.
Accordingly, highly efficient structural genome 
analysis will also greatly contribute to research 
and development in such fields.
5 Recent studies on
 DNA sequencing technology
Technological innovation in DNA sequencing 
has been made on the basis of the Sanger method, 
achieving the invention of the capillary DNA 
sequencer that is widely used today.  Yet, research 
and development of technologies with principles 
other than the Sanger method applied are also 
advancing.  Although such technologies are still 
in the experimental stage, some may be put into 
practical use.  In this section, we will introduce 
to you some of these new technologies.
5.1  Technologies with the Sanger method 
applied
Sequenci ng by mass  spect rometr y  and 
microchips have been reported as technologies 
for highly efficient analysis using the Sanger 
method, as its basic sequencing principle with 
the analyzers devised.
•Sequencing by mass spectrometry
A mass spectrometer can characterize the 
mass of molecules precisely and quickly.  Ionized 
molecules are introduced into a vacuum space 
with a magnetic f ield and the mass of the 
molecules is calculated from the drifting time 
of the ionized molecules.  This method is called 
time - of - f l ight mass spectrometry (TOF -MS). 
Mass  spect rometr y  of  prote i ns  and DNA 
molecules became practicable as the electrospray 
ionization (ESI) and the matrix assisted laser 
desorption ionization (MALDI) were invented 
in the 1980s and ionization of these molecules 
became possible.  Today, MALDI-TOF-MS is often 
used in DNA sequencing.  While the principle 
of sequencing is based on the conventional 
Sanger method, separation of DNA fragments 
is conducted by the mass spectrometer.  In this 
method, separation, detection and analysis of 
DNA fragments are completed on the second 
time scale, and, moreover, only a few hundred 
nanoliters of the sample are required.  Yet, so far, 
only about 100 bp can be analyzed in one course 
of analysis[2].
•Sequencing by microchips
In sequencing by microchips, a microchip 
electrophoresis device in which minute channels 
are formed on a glass or plastic substrate is 
used.  This sequencing technology has the same 
principle as the capillary electrophoresis.  Since 
the microchannels have very small heat capacity, 
high voltage can be applied.  Thus, speedy 
analysis with high separation performance can 
be conducted, and little amounts of samples are 
necessary for analysis.  In addition, semiconductor 
technology is applied in the production of 
this chip, so the experimental system can be 
parallelized through integration with sample 
preparation and detection carried out on one 
chip.  This concept is called “micro total analysis 
system (µTAS)” or “lab-on-a-chip”[2].  Today, the 
experimental course of amplifying DNAs by the 
polymerase chain reaction (PCR) and separating 
its products according to their molecular weights 
with electrophoresis can be conducted on several 
samples in parallel on one chip.  However, a chip 
on which DNA can be sequenced has not yet 
been invented.
5.2 Technologies with other principles applied
Researchers are striving to sequence DNAs 
directly without using the Sanger method 
as in microscopic sequencing and nanopore 
sequencing.  Also, DNA sequencing technology 
using DNA chips has been proposed.
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•Microscopic sequencing
Direct observation of DNAs has become 
possible along with the rapid improvement 
of electron microscopes and scanning probe 
microscopes (SPM).  Some research groups 
are endeavoring to sequence DNAs by directly 
observing bases on the DNA chains, and there 
are reports on the observation of the DNA double 
helix and distinction between adenine and 
thymine[2].
•Nanopore sequencing
In nanopore sequencing, DNA is sequenced 
when it  passes through a nanopore, or a 
nano-level pore, with a diameter slightly larger 
than the molecular diameter of the DNA.  When 
the DNA molecule enters the pore, the electrical 
property of the nanopore changes depending 
on the DNA bases passing.  Researchers are 
attempting to sequence DNAs using this base 
dependency of the electric current.  Since a 
DNA molecule passes a nanopore in several 
milliseconds, rapid sequencing can be realized 
if this nanopore sequencing becomes feasible. 
So far, there has been a report describing the 
difference in change in electrical property 
between polyadenine and polycytosine[2].
•Sequencing with DNA chips
In this method, all kinds of oligonucleotides 
of a specific length are fixed on a DNA chip, and 
the sample to be analyzed is fluorescence-labeled 
and applied to the chip.  The oligonucleotides 
hybridized with the sample indicate that their 
sequences exist in the sample.  Accordingly, the 
sequences of all hybridized oligonucleotides 
are compared and the whole sequence of the 
sample is estimated based on the overlaps of the 
oligonucleotide sequences.  However, there is 
a disadvantage that only a sample with length 
corresponding to the square root of the number 
of oligonucleotides fixed on the substrate can be 
sequenced.  For example, there are 65,536 kinds 
of oligonucleotides with a length of 8 bp, and 
even if a chip contains all these oligonucleotides, 
the maximum length that can be sequenced is 
only 256 bp.  When a longer sample is sequenced, 
far more various kinds of sequences must be 
loaded on the chip.  There is a report that 
sequencing with DNA chips may be put into 
practical use if a large variety of sequences can 
be fixed on the chip and hybridization can be 
detected electronically[6].
5.3 Technology supporting DNA sequencing
Since sequencers today can deal with only a 
limited length of samples, we need to fragment 
DNA when we analyze long sequences l ike 
genomes.  However, fragmentation is carried 
out in vitro and the order of the DNA fragments 
becomes random.  Thus, a f ter sequencing 
each fragment, we need to ascertain overlaps 
between fragments by computer analysis and 
rearrange them.  This step takes time and tends 
to cause mistakes.  As a method to overcome such 
disadvantages, single-molecule DNA sequencing 
has been proposed.
•Single-molecule DNA sequencing
Researchers try to realize single-molecule DNA 
sequencing, in which a single DNA molecule, 
i.e., one DNA strand, is physically fixed linearly 
and fragmented from an end one by one, and the 
fragments are amplified by PCR and sequenced 
with the Sanger method.  This procedure is 
favorable in that we do not need to rearrange 
the DNA fragments after sequencing, because 
the fragments are al igned according to the 
order in the original sample.  There is a report 
that a sample was successfully extended, fixed, 
fragmented and isolated.  Another report says a 
sample could be amplified with PCR from a single 
molecule only[2].
6 Conclusion
Development of the genome analysis technology 
has been emphasized since the start of the Human 
Genome Project.  For example, in the U.S. Human 
Genome Project, certain numerical targets 
for analysis speed and costs were set to boost 
genome sequencing capacity.  Also in Japan, many 
government proposals for promoting human 
genome analysis since 1987 have stressed that the 
nation should advance DNA analysis technology.
As a matter of fact, the Special Coordination 
Funds for Promoting Science and Technology 
of the former Science and Technology Agency 
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supported “Research on development of DNA 
extraction, analysis and synthesis technology” 
from 1981 to 1983 and “Research for development 
of common basic technology for cancer studies” 
from 1984 to 1989.  Moreover, RIKEN promoted 
“Development of the Human Genome Analyzer 
(HUGA)” from 1987 to 1994.
I t  i s  no t a b l e  t h a t  t he  conce pt  o f  t he  
autosequencer was proposed by a Japanese 
researcher.  Japan has obtained and exploited 
fruits of research and development of element 
technologies.  However, in reality, most of the 
sequencers that Japanese laboratories purchase 
are produced by foreign companies.  For example, 
the market share of the capillary DNA sequencers 
of foreign companies in Japan was 99% by value 
in FY2001[7].
Fore f ront  re sea rch  s t a r t s  f rom dev ice  
i nvent ion ,  a nd  i n novat ive  mea su rement  
technologies activate new spheres of study. 
Thus, if we have domestic bases for developing 
state-of-the-art analyzers, we can enhance the 
quality of research and development more and 
more.  Structural genome analysis technology 
contr ibutes to improvements in medicine, 
pharmacy, agr icu lture, the food industr y, 
chemistry, environmental studies and so forth. 
Therefore, progress in structural genome analysis 
technology will elevate the standard of research 
and development of many studies.
Recently, the Japanese government announced 
new programs for developing analyzers.  The 
Biotechnology Strategy Guidelines adopted 
on December 6, 2002 by the Biotechnology 
Strategy Council of the Japanese Cabinet, which 
aims at applying and industr ia l izing fruits 
of biotechnological research, enhancing the 
nation’s quality of life and bolstering industrial 
competitiveness, advocates the promotion of 
cooperation with information technology and 
nanotechnology and intensified investments to 
the development of biotechnological devices. 
Moreover, the policy for distributing resources 
such as budgets and talent in science and 
technology in FY 2004 adopted by the Council 
for Science and Technology Policy, Cabinet Office 
on June 19, 2003 sets development of forefront 
technologies and devices for analysis of genes 
and proteins as a prioritized target in life science. 
In addition, the Ministry of Education, Culture, 
Sports, Science and Technology organized a panel 
on the development of forefront technologies of 
measurement and analysis in June 2003, and is 
scrutinizing how to practically promote research 
and development of devices.
In such a current, we need to encourage 
further research and development with attention 
to several points as follows.
As we enter the post genome era and research 
objects will expand from structural genome 
analysis into functional genome analysis and 
clar i f icat ion of the relat ionsh ip between 
genes and diseases for medical applications, 
genome analysis technology is expected to 
grow vigorously.  Taking this circumstance into 
consideration, we need to continuously back 
up basic research, unveiling new principles and 
applied research to exploit the fruits of basic 
studies.
Furthermore, we should support technologies 
in the development stage until devices applicable 
in laborator ies and medical treatment are 
invented.  We must develop such devices as 
systems including reagents and analysis software.
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 A method for sequencing a single strand 
DNA.  When a polynucleotide chain with 
a sequence complementing a single strand 
DNA is synthesized with enzymes, the 
synthesis can be stopped artificially at a 
proper position of the nucleotides.  That is, 
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(Original Japanese version: published in August 2003)
although deoxyribonucleoside triphosphates 
(dNTPs) serve as the substrate for synthesizing 
complementary sequences, a small amount 
of dideoxyribonucleoside triphosphates 
(ddNTPs) is added to dNTPs.  Enzymes 
incorporate dNTPs and ddNTPs into the DNA 
strand without distinguishing between them. 
When a ddNTP is incorporated, DNA synthesis 
stops.  The polynucleotides produced are 
electrophoresed, separated according to their 
molecular weights, and detected.
*2 Microarray and DNA chip[6]
 In a microarray and DNA chip, particular 
DNAs are al igned at high density on a 
substrate of glass or polymers.  In the 
microarray, DNAs are dripped onto the 
substrate.  On the other hand, in the DNA 
chip, oligonucleotides are synthesized on the 
surface of the chip and DNAs can be aligned 
at higher density than in the microarray. 
When the DNA sample to be analyzed is 
f luorescence - labeled and reacts with the 
DNAs on the substrate, hybridization occurs 
if there are complementary sequences of the 
sample.  Hybridization between the sample 
and the DNAs on the substrate is detected 
with a fluorescence detector and analyzed 
with a computer.
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